Long-term follow-up high-dose chemotherapy (drug-only program) followed by autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas

Clinical Lymphoma

Volumn 6, Issue 1, 2005, Pages 31-36

  Usui, Noriko ^a   Yano, Shingo ^a   Asai, Osamu ^a   Dobashi, Nobuaki ^a   Osawa, Hiroshi ^a   Takei, Yutaka ^a   Sugiyama, Katsuki ^a   Takahara, Shinobu ^a   Otubo, Hiroko ^a   Saito, Takeshi ^a   Okawa, Yutaka ^a   Hagino, Takeshi ^a   Kaito, Ken ^a   Kobayashi, Masayuki ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Carboplatin; Cyclophosphamide; Etoposide; Involved field radiation therapy; Nimustine

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BLEOMYCIN; CARBOPLATIN; CD34 ANTIGEN; CEPHALOSPORIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; NIMUSTINE; PREDNISONE; VINCRISTINE;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BLADDER DISEASE; CANCER SURVIVAL; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG FATALITY; DRUG MEGADOSE; FEASIBILITY STUDY; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL DISEASE; GRANULOCYTOPENIA; HEART DISEASE; HUMAN; IMMUNOPHENOTYPING; KIDNEY DISEASE; LEUKEMIA; LIVER DISEASE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NEUROLOGIC DISEASE; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDY; STEM CELL MOBILIZATION; STOMATITIS; TREATMENT OUTCOME; WHOLE BODY RADIATION; CARDIOTOXICITY; CD34 SELECTION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG RESPONSE; GASTROINTESTINAL TOXICITY; LIVER TOXICITY; LONG TERM CARE; OVERALL SURVIVAL; PERICARDITIS; SURVIVAL RATE;

EID: 22944481887     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2005.n.024     Document Type: Article

References (32)

1. Armitage JO. Treatment of non-Hodgkin's lymphoma. N Engl J Med 1993; 328:14.
2. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328:1002-1006.
3. Klimo P, Connors J. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 1985; 102:596-601.
4. Longo D, DeVita V Jr, Duffey P, et al. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial [published erratum in J Clin Oncol 1991; 9:710]. J Clin Oncol 1991; 9:25-38.
5. Armitage J. Bone marrow transplantation in the treatment of patients with lymphoma. Blood 1989; 73:1749-1758.
6. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333:1540-1545.
7. Vose JM, Zhang MJ, Rowlings PA, et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001; 19:406-413.
8. Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 Protocol - a Groupe d'Etude des Lymphomes de l'Adulte Study. J Clin Oncol 2000; 18:3025-3030.
9. Friedberg JW, Neuberg D, Stone RM, et al. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1999; 17:3128-3135.
10. Metayer C, Curtis RE, Vose J, et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood 2003; 101:2015-2023.
11. Armitage JO, Carbone PP, Connors JM, et al. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 2003; 21:897-906.
12. National Cancer Institute sponsored study of classificatiions of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982; 49:2112-2135.
13. Shipp MA, Abeloff MD, Antman KH, et al. International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. J Clin Oncol 1999; 17:423.
14. Vose JM, Sharp G, Chan WC, et al. Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease. J Clin Oncol 2002; 20:2344-2352.
15. Carbone P, Kaplan H, Musshoff K, et al. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971; 31:1860-1861.
16. McKelvey EM, Gottlieb JA, Wilson HE, et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976; 38:1484-1493.
17. Usui N, Dobashi N, Asai O, et al. Role of oral administration of etoposide in die combination chemotherapy (ABCVEP-I & II) for aggressive histology lymphoma. Proc Am Soc Clin Oncol 1999; 18:39a (Abstract #147).
18. Wilson W, Bates S, Fojo A, et al. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 1995; 13:1995-2004.
19. Asai O, Yano S, Kato A, et al. ACNU-ETOP-CBDCA-CPM followed by autologous hematopoietic stem cell transplantation in refractory aggressive non-Hodgkin's lymphoma. Blood 1998; 92(suppl):360b.
20. Bearman S, Appelbaum F, Buckner C, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6:1562-1568.
21. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481.
22. Petp R, Pike N, Armitage P. Design and analysis of randomized clinical trial requiring prolonged observation of each patient. II analysis and examples. Br J Cancer 1977; 35:1-39.
23. Haioun C, Lepage E, Gisselbrecht C, et al. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1994; 12:2543-2551.
24. Gianni AM, Bregni M, Siena S, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336:1290-1297.
25. Santini G, Salvagno S, Leoni P, et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the Non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol 1998; 16:2796-2802.
26. Haioun C, Lepage E, Gisselbrecht C, et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997; 15:1131-1137.
27. Martelli M, Gherlinzoni F, De Renzo A, et al. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. J Clin Oncol 2003; 21:1255-1262.
28. Kewalramani T, Zelenetz AD, Hedrick EE, et al. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. Blood 2000; 96:2399-2404.
29. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329:984-987.
30. Cortelazzo S, Rambaldi A, Rossi A, et al. Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin's lymphoma. Br J Haematol 2001; 114:333-341.
31. Stiff PJ, Dahlberg S, Forman SJ, et al. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens - a Southwest Oncology Group trial. J Clin Oncol 1998; 16:48-55.
32. Hamlin PA, Zelenetz AD, Kewalramani T, et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003; 102:1989-1996.